---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009590"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:31:47.043330+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioCardia FY2023 net loss $11.6M; CardiAMP HF trial misses primary endpoint but subgroup shows benefit

## Summary
- Revenue $0.5M (down from $1.4M); net loss $11.6M; cash $1.1M at year-end; financing provides runway into Q2 2024.
- CardiAMP HF trial missed primary endpoint; interim data: 37% RR reduction in heart death equivalents overall.
- In NTproBNP-elevated subgroup (59% of patients): 86.2% RR reduction in heart death equivalents (2.9% vs 21.1%).
- Confirmatory Phase III CardiAMP HF II trial approved by FDA with >90% power; Medicare reimbursement certified.
- Morph DNA steerable sheath family expects FDA approval Q3 2024; two additional biotherapeutic delivery partnerships anticipated.

## SEC filing metadata
- accession: 0001437749-24-009590
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774924009590/0001437749-24-009590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774924009590/bcda20240326_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009590
- JSON: https://secwatch.observer/filing/0001437749-24-009590.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009590.txt

## Key facts
- Earnings Releases
  BioCardia, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 27, 2024, BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/925741/000143774924009590/0001437749-24-009590-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.